Pharmaceuticals (Jun 2021)

Update on PET Tracer Development for Muscarinic Acetylcholine Receptors

  • Marius Ozenil,
  • Jonas Aronow,
  • Marlon Millard,
  • Thierry Langer,
  • Wolfgang Wadsak,
  • Marcus Hacker,
  • Verena Pichler

DOI
https://doi.org/10.3390/ph14060530
Journal volume & issue
Vol. 14, no. 6
p. 530

Abstract

Read online

The muscarinic cholinergic system regulates peripheral and central nervous system functions, and, thus, their potential as a therapeutic target for several neurodegenerative diseases is undoubted. A clinically applicable positron emission tomography (PET) tracer would facilitate the monitoring of disease progression, elucidate the role of muscarinic acetylcholine receptors (mAChR) in disease development and would aid to clarify the diverse natural functions of mAChR regulation throughout the nervous system, which still are largely unresolved. Still, no mAChR PET tracer has yet found broad clinical application, which demands mAChR tracers with improved imaging properties. This paper reviews strategies of mAChR PET tracer design and summarizes the binding properties and preclinical evaluation of recent mAChR tracer candidates. Furthermore, this work identifies the current major challenges in mAChR PET tracer development and provides a perspective on future developments in this area of research.

Keywords